NASDAQ:ACER - Acer Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$18.80 -0.17 (-0.90 %)
(As of 05/24/2018 04:10 AM ET)
Previous Close$18.97
Today's Range$18.73 - $19.10
52-Week Range$5.69 - $22.63
Volume28,500 shs
Average Volume22,762 shs
Market Capitalization$142.30 million
P/E Ratio-4.88
Dividend YieldN/A
Beta2.36

About Acer Therapeutics (NASDAQ:ACER)

Acer Therapeutics logoAcer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.

Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100

Debt

Debt-to-Equity RatioN/A
Current Ratio5.34
Quick Ratio5.34

Price-To-Earnings

Trailing P/E Ratio-4.88
Forward P/E Ratio-7.97
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.90 million
Price / Sales48.62
Cash FlowN/A
Price / CashN/A
Book Value$2.48 per share
Price / Book7.58

Profitability

EPS (Most Recent Fiscal Year)($3.84)
Net Income$-14,190,000.00
Net MarginsN/A
Return on Equity-86.30%
Return on Assets-76.75%

Miscellaneous

Employees6
Outstanding Shares7,500,000

Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics (NASDAQ:ACER) released its quarterly earnings data on Monday, May, 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.16. View Acer Therapeutics' Earnings History.

What price target have analysts set for ACER?

3 Wall Street analysts have issued 1-year target prices for Acer Therapeutics' stock. Their forecasts range from $50.00 to $70.00. On average, they expect Acer Therapeutics' share price to reach $60.00 in the next year. View Analyst Ratings for Acer Therapeutics.

Who are some of Acer Therapeutics' key competitors?

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the folowing people:
  • Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 42)
  • Mr. Harry S. Palmin, Chief Financial Officer (Age 48)
  • Mr. Jefferson Davis, Acting Chief Bus. Officer (Age 51)
  • Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 53)
  • Ms. Kim Tharaldsen, Sr. Director of Marketing

Has Acer Therapeutics been receiving favorable news coverage?

Media stories about ACER stock have trended somewhat positive on Thursday, Accern reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acer Therapeutics earned a media sentiment score of 0.13 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 47.20 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Acer Therapeutics' major shareholders?

Acer Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Heartland Advisors Inc. (0.74%) and Neuberger Berman Group LLC (0.27%). Company insiders that own Acer Therapeutics stock include Steve Aselage and Timothy C Barabe. View Institutional Ownership Trends for Acer Therapeutics.

Which major investors are buying Acer Therapeutics stock?

ACER stock was purchased by a variety of institutional investors in the last quarter, including Heartland Advisors Inc. and Neuberger Berman Group LLC. View Insider Buying and Selling for Acer Therapeutics.

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $18.80.

How big of a company is Acer Therapeutics?

Acer Therapeutics has a market capitalization of $142.30 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-14,190,000.00 in net income (profit) each year or ($3.84) on an earnings per share basis. Acer Therapeutics employs 6 workers across the globe.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]


MarketBeat Community Rating for Acer Therapeutics (ACER)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe ACER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acer Therapeutics (NASDAQ:ACER) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Acer Therapeutics in the last 12 months. Their average twelve-month price target is $60.00, suggesting that the stock has a possible upside of 219.15%. The high price target for ACER is $70.00 and the low price target for ACER is $50.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $60.00$60.00$50.00N/A
Price Target Upside: 219.15% upside226.09% upside195.68% upsideN/A

Acer Therapeutics (NASDAQ:ACER) Consensus Price Target History

Price Target History for Acer Therapeutics (NASDAQ:ACER)

Acer Therapeutics (NASDAQ:ACER) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/22/2018HC WainwrightSet Price TargetBuy$50.00LowView Rating Details
2/26/2018Roth CapitalInitiated CoverageBuy ➝ Buy$70.00HighView Rating Details
2/16/2018William BlairInitiated CoverageOutperformHighView Rating Details
10/28/2016Maxim GroupDowngradeBuy ➝ HoldN/AView Rating Details
10/28/2016Chardan CapitalDowngradeBuy ➝ NeutralN/AView Rating Details
10/28/2016AegisDowngradeBuy ➝ HoldN/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Acer Therapeutics (NASDAQ:ACER) Earnings History and Estimates Chart

Earnings by Quarter for Acer Therapeutics (NASDAQ:ACER)

Acer Therapeutics (NASDAQ:ACER) Earnings Estimates

2018 EPS Consensus Estimate: ($2.37)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.69)($0.69)($0.69)
Q2 20181($0.57)($0.57)($0.57)
Q3 20181($0.54)($0.54)($0.54)
Q4 20181($0.57)($0.57)($0.57)

Acer Therapeutics (NASDAQ ACER) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018Q1 2018($0.69)($0.53)ViewN/AView Earnings Details
3/7/2018Q4 2017($0.53)($0.63)ViewN/AView Earnings Details
11/13/2017Q3 2017($1.09)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.93)ViewN/AView Earnings Details
5/12/2017Q1 2017($0.12)ViewN/AView Earnings Details
3/28/2017Q4 2016($1.04)$0.73 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.25)($0.28)$0.73 millionViewN/AView Earnings Details
8/11/2016Q216($0.23)($0.30)$0.73 million$0.73 millionViewListenView Earnings Details
5/12/2016Q116($0.35)($0.31)$0.73 million$0.73 millionViewListenView Earnings Details
3/15/2016Q415($0.50)($2.05)$0.73 million$0.73 millionViewListenView Earnings Details
11/10/2015Q315($2.48)($0.42)$0.73 million$0.73 millionViewN/AView Earnings Details
8/12/2015Q215($0.08)($0.07)$0.73 millionViewListenView Earnings Details
5/12/2015Q1($0.15)($0.12)$0.38 millionViewListenView Earnings Details
2/23/2015Q4 2014($9.94)$0.31 millionViewN/AView Earnings Details
11/6/2014($0.14)($0.12)$0.30 million$0.31 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.15)$0.30 million$0.31 millionViewN/AView Earnings Details
5/14/2014Q114($0.13)($0.13)$0.2201 million$0.3488 millionViewN/AView Earnings Details
11/7/2013Q3 2013($32.30)$0.35 millionViewN/AView Earnings Details
8/14/2013Q213($0.37)$0.3488 millionViewN/AView Earnings Details
5/14/2013Q1 2013($48.03)$0.22 millionViewN/AView Earnings Details
11/14/2012Q312($0.10)ViewN/AView Earnings Details
8/13/2012Q2 2012($31.14)ViewN/AView Earnings Details
5/11/2012Q1 2012($34.12)ViewN/AView Earnings Details
2/27/2012Q4 2011($26.50)ViewN/AView Earnings Details
11/4/2011Q3 2011($18.55)ViewN/AView Earnings Details
8/11/2011Q2 2011($21.20)ViewN/AView Earnings Details
5/6/2011Q1 2011($20.54)ViewN/AView Earnings Details
3/8/2011Q4 2010($16.56)ViewN/AView Earnings Details
11/9/2010Q3 2010($23.19)ViewN/AView Earnings Details
8/6/2010Q2 2010($26.50)($38.10)ViewN/AView Earnings Details
5/13/2010Q1 2010($26.50)($30.48)ViewN/AView Earnings Details
3/5/2010Q4 2009($29.81)ViewN/AView Earnings Details
11/4/2009Q3 2009$7.29ViewN/AView Earnings Details
8/13/2009Q2 2009($2,030.97)ViewN/AView Earnings Details
5/15/2009Q1 2009($44.39)ViewN/AView Earnings Details
4/16/2009Q4 2008($43.06)ViewN/AView Earnings Details
10/23/2008Q3 2008($102.69)($91.10)ViewN/AView Earnings Details
8/14/2008Q2 2008($125.88)($117.93)ViewN/AView Earnings Details
5/13/2008Q1 2008($162.32)($123.56)ViewN/AView Earnings Details
3/18/2008Q4 2007($188.82)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Acer Therapeutics (NASDAQ:ACER) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Acer Therapeutics (NASDAQ ACER) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 25.70%
Institutional Ownership Percentage: 8.17%
Insider Trading History for Acer Therapeutics (NASDAQ:ACER)
Insider Trading History for Acer Therapeutics (NASDAQ:ACER)

Acer Therapeutics (NASDAQ ACER) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2017Steve AselageDirectorBuy2,000$12.00$24,000.00View SEC Filing  
11/18/2016Timothy C BarabeDirectorSell14,914$0.55$8,202.7020,719View SEC Filing  
9/17/2014Timothy C BarabeDirectorBuy10,000$1.15$11,500.00View SEC Filing  
9/16/2014Neil K WarmaCEOBuy10,000$1.11$11,100.00View SEC Filing  
12/18/2013Karthik RadhakrishnanCFOBuy8,000$1.70$13,600.00View SEC Filing  
12/18/2013Scott B SeamanDirectorBuy30,000$1.70$51,000.00View SEC Filing  
8/8/2013Karthik RadhakrishnanCFOBuy50,000$1.50$75,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Acer Therapeutics (NASDAQ ACER) News Headlines

Source:
DateHeadline
-$0.57 EPS Expected for Acer Therapeutics (ACER) This Quarter-$0.57 EPS Expected for Acer Therapeutics (ACER) This Quarter
www.americanbankingnews.com - May 23 at 11:30 AM
Why Opexa Therapeutics (ACER) Could Shock the Market SoonWhy Opexa Therapeutics (ACER) Could Shock the Market Soon
finance.yahoo.com - May 22 at 4:39 PM
HC Wainwright Analysts Give Acer Therapeutics (ACER) a $50.00 Price TargetHC Wainwright Analysts Give Acer Therapeutics (ACER) a $50.00 Price Target
www.americanbankingnews.com - May 22 at 9:45 AM
Zacks: Acer Therapeutics (ACER) Receives Average Rating of "Strong Buy" from BrokeragesZacks: Acer Therapeutics (ACER) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - May 18 at 1:43 PM
Acer Therapeutics (ACER) Lifted to Buy at Zacks Investment ResearchAcer Therapeutics (ACER) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - May 17 at 4:33 PM
William Blair Brokers Raise Earnings Estimates for Acer Therapeutics (ACER)William Blair Brokers Raise Earnings Estimates for Acer Therapeutics (ACER)
www.americanbankingnews.com - May 17 at 7:00 AM
Acer Therapeutics on track for Edsivo NDA in June/JulyAcer Therapeutics on track for Edsivo NDA in June/July
seekingalpha.com - May 15 at 9:31 AM
Acer Therapeutics (ACER) Issues Quarterly  Earnings ResultsAcer Therapeutics (ACER) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 15 at 7:35 AM
Acer Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate UpdateAcer Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 14 at 4:48 PM
Zacks Investment Research Upgrades Acer Therapeutics (ACER) to "Hold"Zacks Investment Research Upgrades Acer Therapeutics (ACER) to "Hold"
www.americanbankingnews.com - May 9 at 5:09 PM
Acer Therapeutics (ACER) Expected to Post Earnings of -$0.69 Per ShareAcer Therapeutics (ACER) Expected to Post Earnings of -$0.69 Per Share
www.americanbankingnews.com - May 6 at 1:24 AM
Acer Therapeutics (ACER) Upgraded by ValuEngine to HoldAcer Therapeutics (ACER) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - May 4 at 3:41 PM
Zacks: Acer Therapeutics (ACER) Given Average Recommendation of "Strong Buy" by BrokeragesZacks: Acer Therapeutics (ACER) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 30 at 5:20 PM
-$0.69 Earnings Per Share Expected for Acer Therapeutics Inc (ACER) This Quarter-$0.69 Earnings Per Share Expected for Acer Therapeutics Inc (ACER) This Quarter
www.americanbankingnews.com - April 19 at 1:16 AM
ValuEngine Downgrades Acer Therapeutics (ACER) to SellValuEngine Downgrades Acer Therapeutics (ACER) to Sell
www.americanbankingnews.com - April 8 at 2:04 PM
Zacks: Brokerages Expect Acer Therapeutics Inc (ACER) to Post -$0.69 Earnings Per ShareZacks: Brokerages Expect Acer Therapeutics Inc (ACER) to Post -$0.69 Earnings Per Share
www.americanbankingnews.com - April 2 at 1:16 AM
Zacks: Brokerages Set $60.00 Price Target for Acer Therapeutics Inc (ACER)Zacks: Brokerages Set $60.00 Price Target for Acer Therapeutics Inc (ACER)
www.americanbankingnews.com - March 31 at 1:20 AM
HC Wainwright Reiterates "$50.00" Price Target for Acer Therapeutics (ACER)HC Wainwright Reiterates "$50.00" Price Target for Acer Therapeutics (ACER)
www.americanbankingnews.com - March 30 at 3:58 PM
 Acer Therapeutics Inc (ACER) Given $60.00 Consensus Target Price by Brokerages Acer Therapeutics Inc (ACER) Given $60.00 Consensus Target Price by Brokerages
www.americanbankingnews.com - March 16 at 1:32 PM
Zacks: Analysts Expect Acer Therapeutics Inc (ACER) Will Announce Earnings of -$0.69 Per ShareZacks: Analysts Expect Acer Therapeutics Inc (ACER) Will Announce Earnings of -$0.69 Per Share
www.americanbankingnews.com - March 15 at 11:14 PM
 Acer Therapeutics Inc (ACER) Receives Consensus Recommendation of "Buy" from Brokerages Acer Therapeutics Inc (ACER) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 13 at 3:20 AM
William Blair Comments on Acer Therapeutics Incs Q1 2018 Earnings (ACER)William Blair Comments on Acer Therapeutics Inc's Q1 2018 Earnings (ACER)
www.americanbankingnews.com - March 12 at 2:50 AM
Acer Therapeutics (ACER) Given a $50.00 Price Target by HC Wainwright AnalystsAcer Therapeutics (ACER) Given a $50.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 9 at 10:14 PM
Acer Therapeutics (ACER) Lowered to "Sell" at Zacks Investment ResearchAcer Therapeutics (ACER) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 9 at 4:54 PM
Acer Therapeutics Inc (ACER) to Post FY2020 Earnings of $0.65 Per Share, William Blair ForecastsAcer Therapeutics Inc (ACER) to Post FY2020 Earnings of $0.65 Per Share, William Blair Forecasts
www.americanbankingnews.com - March 9 at 3:57 PM
Acer Therapeutics (ACER) Releases  Earnings Results, Misses Estimates By $0.10 EPSAcer Therapeutics (ACER) Releases Earnings Results, Misses Estimates By $0.10 EPS
www.americanbankingnews.com - March 8 at 9:47 AM
Acer Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate UpdateAcer Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 7 at 5:39 PM
Stonepine Capital Management LLC Buys New Stake in Acer Therapeutics Inc (ACER)Stonepine Capital Management LLC Buys New Stake in Acer Therapeutics Inc (ACER)
www.americanbankingnews.com - March 6 at 10:02 AM
Acer Therapeutics to Present at the 30th Annual ROTH ConferenceAcer Therapeutics to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 6 at 8:58 AM
 Brokerages Expect Acer Therapeutics Inc (ACER) to Announce -$0.62 Earnings Per Share Brokerages Expect Acer Therapeutics Inc (ACER) to Announce -$0.62 Earnings Per Share
www.americanbankingnews.com - February 26 at 11:28 PM
Acer Therapeutics (ACER) Earns Buy Rating from Analysts at Roth CapitalAcer Therapeutics (ACER) Earns Buy Rating from Analysts at Roth Capital
www.americanbankingnews.com - February 26 at 2:42 PM
 Acer Therapeutics Inc (ACER) Given Average Rating of "Buy" by Analysts Acer Therapeutics Inc (ACER) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 25 at 7:08 PM
 Acer Therapeutics Inc (ACER) Given $50.00 Average Target Price by Analysts Acer Therapeutics Inc (ACER) Given $50.00 Average Target Price by Analysts
www.americanbankingnews.com - February 20 at 5:32 PM
Acer Therapeutics (ACER) Earns Outperform Rating from Analysts at William BlairAcer Therapeutics (ACER) Earns Outperform Rating from Analysts at William Blair
www.americanbankingnews.com - February 16 at 10:28 PM
Zacks: Brokerages Expect Acer Therapeutics Inc (ACER) Will Announce Earnings of -$0.62 Per ShareZacks: Brokerages Expect Acer Therapeutics Inc (ACER) Will Announce Earnings of -$0.62 Per Share
www.americanbankingnews.com - February 10 at 7:24 AM
Global Orphan Drugs IndustryGlobal Orphan Drugs Industry
www.bizjournals.com - February 6 at 4:12 PM
Acer Therapeutics Expands Management Team with the Appointment of Three Executives and One New Key HireAcer Therapeutics Expands Management Team with the Appointment of Three Executives and One New Key Hire
finance.yahoo.com - February 5 at 9:22 AM
Acer Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare ConferenceAcer Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - January 31 at 9:48 AM
Critical Comparison: Acer Therapeutics (ACER) and Cytokinetics (CYTK)Critical Comparison: Acer Therapeutics (ACER) and Cytokinetics (CYTK)
www.americanbankingnews.com - January 30 at 7:56 AM
Zacks: Brokerages Anticipate Acer Therapeutics Inc (ACER) Will Post Earnings of -$0.62 Per ShareZacks: Brokerages Anticipate Acer Therapeutics Inc (ACER) Will Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - January 24 at 9:12 AM
Zacks: Opexa Therapeutics, Inc. (ACER) Given Average Recommendation of "Buy" by BrokeragesZacks: Opexa Therapeutics, Inc. (ACER) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 9 at 5:10 AM
Opexa Therapeutics, Inc. (ACER) Expected to Post Earnings of -$0.62 Per ShareOpexa Therapeutics, Inc. (ACER) Expected to Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - January 7 at 3:08 AM
Acer Therapeutics to Present at the Biotech Showcase™ 2018 ConferenceAcer Therapeutics to Present at the Biotech Showcase™ 2018 Conference
finance.yahoo.com - January 3 at 6:00 PM
Reviewing Opexa Therapeutics (ACER) & TRACON Pharmaceuticals (TCON)Reviewing Opexa Therapeutics (ACER) & TRACON Pharmaceuticals (TCON)
www.americanbankingnews.com - December 31 at 7:30 AM
Opexa Therapeutics (ACER) Rating Lowered to Sell at ValuEngineOpexa Therapeutics (ACER) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 30 at 11:18 AM
Acer Therapeutics Announces Partial Exercise of Over-allotment Option in Public OfferingAcer Therapeutics Announces Partial Exercise of Over-allotment Option in Public Offering
finance.yahoo.com - December 28 at 5:18 PM
Opexa Therapeutics (ACER) Now Covered by Analysts at HC WainwrightOpexa Therapeutics (ACER) Now Covered by Analysts at HC Wainwright
www.americanbankingnews.com - December 20 at 8:06 PM
Opexa Therapeutics, Inc. (ACER) Director Acquires $24,000.00 in StockOpexa Therapeutics, Inc. (ACER) Director Acquires $24,000.00 in Stock
www.americanbankingnews.com - December 18 at 6:52 PM
Acer Therapeutics Announces Closing of Underwritten Public Offering of Common StockAcer Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
finance.yahoo.com - December 14 at 6:28 PM
Acer Therapeutics Announces Proposed Underwritten Public Offering of Common StockAcer Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
finance.yahoo.com - December 11 at 6:11 PM

SEC Filings

Acer Therapeutics (NASDAQ:ACER) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Acer Therapeutics (NASDAQ:ACER) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Acer Therapeutics (NASDAQ ACER) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.